We hypothesized that anlotinib could improve the clinical outcomes via blocking the angiogenesis in ALK-positive NSCLC patients, but the underlying molecular mechanism has not been fully clarified yet. The gene discussed is ALK; the disease is non-small cell lung carcinoma.